JP2024524373A5 - - Google Patents
Info
- Publication number
- JP2024524373A5 JP2024524373A5 JP2023580454A JP2023580454A JP2024524373A5 JP 2024524373 A5 JP2024524373 A5 JP 2024524373A5 JP 2023580454 A JP2023580454 A JP 2023580454A JP 2023580454 A JP2023580454 A JP 2023580454A JP 2024524373 A5 JP2024524373 A5 JP 2024524373A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- alkyl
- substituted
- independently selected
- halo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163215901P | 2021-06-28 | 2021-06-28 | |
| US63/215,901 | 2021-06-28 | ||
| PCT/US2022/035122 WO2023278326A1 (en) | 2021-06-28 | 2022-06-27 | Cdk2 inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024524373A JP2024524373A (ja) | 2024-07-05 |
| JP2024524373A5 true JP2024524373A5 (enExample) | 2025-07-02 |
Family
ID=82655170
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023580454A Pending JP2024524373A (ja) | 2021-06-28 | 2022-06-27 | Ｃｄｋ２阻害剤 |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US11932648B2 (enExample) |
| EP (1) | EP4363423A1 (enExample) |
| JP (1) | JP2024524373A (enExample) |
| KR (1) | KR20240046167A (enExample) |
| CN (1) | CN117897384A (enExample) |
| AR (1) | AR126251A1 (enExample) |
| AU (1) | AU2022301047A1 (enExample) |
| CA (1) | CA3223223A1 (enExample) |
| CL (1) | CL2023003965A1 (enExample) |
| CO (1) | CO2024000237A2 (enExample) |
| CR (1) | CR20230598A (enExample) |
| DO (1) | DOP2023000280A (enExample) |
| EC (1) | ECSP24006831A (enExample) |
| IL (1) | IL309118A (enExample) |
| MX (1) | MX2024000230A (enExample) |
| PE (1) | PE20250123A1 (enExample) |
| TW (1) | TW202317574A (enExample) |
| UY (1) | UY39832A (enExample) |
| WO (1) | WO2023278326A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20240020735A (ko) | 2021-05-07 | 2024-02-15 | 카이메라 쎄라퓨틱스 인코포레이티드 | Cdk2 분해제 및 그 용도 |
| US11932648B2 (en) * | 2021-06-28 | 2024-03-19 | Blueprint Medicines Corporation | CDK2 inhibitors |
| US20240247001A1 (en) | 2022-12-16 | 2024-07-25 | Astrazeneca Ab | 2,6,9-trisubstituted purines |
| WO2024148089A1 (en) * | 2023-01-04 | 2024-07-11 | Blueprint Medicines Corporation | Cdk2 inhibitors |
| JP2026501701A (ja) * | 2023-01-04 | 2026-01-16 | ブループリント メディシンズ コーポレイション | Ｃｄｋ２阻害剤の固体形態 |
| CN120813586A (zh) * | 2023-01-04 | 2025-10-17 | 缆图药品公司 | Cdk2抑制剂 |
| EP4646416A1 (en) * | 2023-01-04 | 2025-11-12 | Blueprint Medicines Corporation | Cdk2 inhibitors |
| CN121311229A (zh) | 2023-02-10 | 2026-01-09 | 缆图药品公司 | 用于治疗癌症的cdk2抑制剂blu-222 |
| UY40638A (es) | 2023-02-17 | 2024-08-30 | Novartis Ag | Inhibidores de quinasa dependientes de ciclina (cdk2) |
| WO2025188779A1 (en) | 2024-03-04 | 2025-09-12 | Blueprint Medicines Corporation | Cdk2 inhibitors for treatment of cancer |
| WO2026024674A1 (en) | 2024-07-22 | 2026-01-29 | Genesis Therapeutics, Inc. | Methods of treating skp2-associated cancers |
| WO2026038120A1 (en) * | 2024-08-12 | 2026-02-19 | Novartis Ag | Synthesis and crystalline forms of a cdk2 inhibitor |
| WO2026050766A1 (en) * | 2024-09-02 | 2026-03-05 | Blueprint Medicines Corporation | Intermediate salts for synthesis of a cdk2 inhibitor |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ523656A (en) | 2000-08-31 | 2004-11-26 | Pfizer Prod Inc | Pyrazole derivatives and their use as protein kinase inhibitors |
| WO2002022605A1 (en) | 2000-09-15 | 2002-03-21 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| US6989385B2 (en) | 2000-12-21 | 2006-01-24 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| AU2003286711A1 (en) | 2002-10-25 | 2004-05-13 | Vertex Pharmaceuticals Incorporated | Indazolinone compositions useful as kinase inhibitors |
| MXPA06007820A (es) | 2004-01-09 | 2006-09-01 | Novartis Ag | Derivados de fenil-[4-(3-fenil-1h-pirazol-4-il)-pirimidin-2-il]-amina como inhibidores de igf-ir. |
| US7405220B2 (en) * | 2004-06-09 | 2008-07-29 | Hoffmann-La Roche Inc. | Pyrazolopyrimidines |
| US8362031B2 (en) | 2004-08-20 | 2013-01-29 | University Of Kansas | Lonidamine analogues and treatment of polycystic kidney disease |
| ES2347172T3 (es) | 2005-02-16 | 2010-10-26 | Astrazeneca Ab | Compuestos quimicos. |
| FR2889526B1 (fr) | 2005-08-04 | 2012-02-17 | Aventis Pharma Sa | 7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation |
| EP1926734A1 (en) * | 2005-08-22 | 2008-06-04 | Amgen Inc. | Pyrazolopyridine and pyrazolopyrimidine compounds useful as kinase enzymes modulators |
| WO2008117050A1 (en) | 2007-03-27 | 2008-10-02 | Astrazeneca Ab | Pyrazolyl-amino-substituted pyrazines and their use for the treatment of cancer |
| JP2010524911A (ja) * | 2007-04-18 | 2010-07-22 | アストラゼネカ アクチボラグ | ５−アミノピラゾール−３−イル−３Ｈ−イミダゾ［４，５−ｂ］ピリジン誘導体と癌の治療のためのその使用 |
| CN101970440A (zh) * | 2007-11-28 | 2011-02-09 | 先灵公司 | 作为蛋白激酶抑制剂的2-氟吡唑并[1，5-a]嘧啶类 |
| DE102008063992A1 (de) | 2008-12-19 | 2010-09-02 | Lerner, Zinoviy, Dipl.-Ing. | Neue aliphatisch substituierte Pyrazolopyridine und ihre Verwendung |
| KR20110049217A (ko) | 2009-11-04 | 2011-05-12 | 다우어드밴스드디스플레이머티리얼 유한회사 | 신규한 유기 발광 화합물 및 이를 채용하고 있는 유기 전계 발광 소자 |
| EA030141B1 (ru) | 2009-12-31 | 2018-06-29 | Хатчисон Медифарма Лимитед | Определенные триазолопиридины и триазолопиразины, их композиции и способы их применения |
| JO3145B1 (ar) | 2010-11-08 | 2017-09-20 | Lilly Co Eli | مركبات مفيدة لتثبيط chk1 |
| KR20120063283A (ko) | 2010-12-07 | 2012-06-15 | 제일약품주식회사 | 신규한 피라졸로 피리딘 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 포함하는 약학적 조성물 |
| WO2013026021A2 (en) | 2011-08-18 | 2013-02-21 | Buck Institute For Research On Aging | Trka as a target for inhibiting app cleavage and/or progression of alzheimer's disease |
| WO2014181287A1 (en) | 2013-05-09 | 2014-11-13 | Piramal Enterprises Limited | Heterocyclyl compounds and uses thereof |
| PT2994465T (pt) | 2013-05-10 | 2018-10-25 | Karus Therapeutics Ltd | Novos inibidores de histona desacetilase |
| RS58361B1 (sr) | 2013-07-31 | 2019-03-29 | Merck Patent Gmbh | Piridini, pirimidini i pirazini, kao inhibitori btk i njihova upotreba |
| WO2016057322A1 (en) | 2014-10-08 | 2016-04-14 | Salk Institute For Biological Studies | Ppar agonists and methods of use thereof |
| SI3302448T1 (sl) | 2015-06-04 | 2024-03-29 | Aurigene Oncology Limited | Substituirani heterociklični derivati kot inhibitorji cdk |
| EP3548034A4 (en) | 2016-12-05 | 2020-07-08 | Microbiotix, Inc. | BROAD SPECTRUM INHIBITORS OF FILOVIRUS |
| US12138263B2 (en) | 2018-03-21 | 2024-11-12 | Relay Therapeutics, Inc. | Pyrazolo[3,4-b]pyrazine SHP2 phosphatase inhibitors and methods of use thereof |
| GB201808093D0 (en) | 2018-05-18 | 2018-07-04 | Enterprise Therapeutics Ltd | Compounds |
| WO2020108516A1 (zh) | 2018-11-27 | 2020-06-04 | 江苏豪森药业集团有限公司 | 含氮杂芳类衍生物调节剂、其制备方法和应用 |
| WO2020108613A1 (zh) * | 2018-11-30 | 2020-06-04 | 江苏豪森药业集团有限公司 | 杂芳类衍生物调节剂、其制备方法和应用 |
| IL284589B2 (en) | 2019-01-31 | 2025-10-01 | Pfizer | 3–Carbonylamino–5–cyclopentyl–h1–pyrazole compounds with cdk2 inhibitory activity |
| PH12021551976A1 (en) | 2019-02-15 | 2022-07-04 | Incyte Corp | Cyclin-dependent kinase 2 biomarkers and uses thereof |
| WO2020205560A1 (en) | 2019-03-29 | 2020-10-08 | Incyte Corporation | Sulfonylamide compounds as cdk2 inhibitors |
| EP3990443A1 (en) | 2019-06-28 | 2022-05-04 | GB002, Inc. | Heterocyclic kinase inhibitors and products and uses thereof |
| US11851426B2 (en) | 2019-10-11 | 2023-12-26 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
| US11634424B2 (en) | 2019-11-29 | 2023-04-25 | Medshine Discovery Inc. | Diazaindole derivative and use thereof as CHK1 inhibitor |
| CN113135896B (zh) | 2020-01-18 | 2024-12-06 | 正大天晴药业集团股份有限公司 | 作为ret抑制剂的甲基吡唑类衍生物 |
| CN114057733A (zh) | 2020-08-07 | 2022-02-18 | 海思科医药集团股份有限公司 | 一种并环杂环衍生物及其在医药上的应用 |
| US20230348475A1 (en) | 2020-09-17 | 2023-11-02 | The Translational Genomics Research Institute | Imidazopyridazine and imidazopyrazine compounds as inhibitors of cdk7 |
| WO2022174031A1 (en) | 2021-02-12 | 2022-08-18 | Relay Therapeutics, Inc. | Cdk inhibitors and methods of use thereof |
| WO2022184130A1 (zh) | 2021-03-03 | 2022-09-09 | 成都先导药物开发股份有限公司 | 一种nuak抑制剂及其用途 |
| KR20240005751A (ko) | 2021-04-12 | 2024-01-12 | 에이2에이 파마수티칼스, 잉크. | 암 치료를 위한 조성물 및 방법 |
| WO2022245776A1 (en) | 2021-05-20 | 2022-11-24 | Saint John's Cancer Institute | Anti-cdk inhibitors for cancer treatment |
| MX2023015245A (es) | 2021-06-16 | 2024-01-19 | Blueprint Medicines Corp | Pirimidinil-pirazoles sustituidos como inhibidores de cdk2. |
| US11981671B2 (en) | 2021-06-21 | 2024-05-14 | Incyte Corporation | Bicyclic pyrazolyl amines as CDK2 inhibitors |
| US11932648B2 (en) | 2021-06-28 | 2024-03-19 | Blueprint Medicines Corporation | CDK2 inhibitors |
| WO2023092088A1 (en) | 2021-11-19 | 2023-05-25 | Blueprint Medicines Corporation | Cdk2 inhibitors and methods of making and using same |
| IL317242A (en) | 2022-06-20 | 2025-01-01 | Incyclix Bio Llc | Cyclin-dependent kinase 2 inhibitors for medical treatment |
| CN117717565A (zh) | 2022-09-16 | 2024-03-19 | 北京悦康科创医药科技股份有限公司 | 反义寡核苷酸在制备治疗食管癌药物中的应用 |
| WO2024148089A1 (en) | 2023-01-04 | 2024-07-11 | Blueprint Medicines Corporation | Cdk2 inhibitors |
| JP2026501701A (ja) | 2023-01-04 | 2026-01-16 | ブループリント メディシンズ コーポレイション | Ｃｄｋ２阻害剤の固体形態 |
| EP4646416A1 (en) | 2023-01-04 | 2025-11-12 | Blueprint Medicines Corporation | Cdk2 inhibitors |
| CN120813586A (zh) | 2023-01-04 | 2025-10-17 | 缆图药品公司 | Cdk2抑制剂 |
| CN121311229A (zh) | 2023-02-10 | 2026-01-09 | 缆图药品公司 | 用于治疗癌症的cdk2抑制剂blu-222 |
| KR20260010389A (ko) | 2023-04-14 | 2026-01-20 | 블루프린트 메디신즈 코포레이션 | Cdk2 억제제 |
-
2022
- 2022-06-27 US US17/850,453 patent/US11932648B2/en active Active
- 2022-06-27 IL IL309118A patent/IL309118A/en unknown
- 2022-06-27 PE PE2023003487A patent/PE20250123A1/es unknown
- 2022-06-27 MX MX2024000230A patent/MX2024000230A/es unknown
- 2022-06-27 WO PCT/US2022/035122 patent/WO2023278326A1/en not_active Ceased
- 2022-06-27 TW TW111123974A patent/TW202317574A/zh unknown
- 2022-06-27 UY UY0001039832A patent/UY39832A/es unknown
- 2022-06-27 EP EP22744613.5A patent/EP4363423A1/en active Pending
- 2022-06-27 KR KR1020247003175A patent/KR20240046167A/ko active Pending
- 2022-06-27 JP JP2023580454A patent/JP2024524373A/ja active Pending
- 2022-06-27 AR ARP220101677A patent/AR126251A1/es unknown
- 2022-06-27 CN CN202280057725.7A patent/CN117897384A/zh active Pending
- 2022-06-27 CR CR20230598A patent/CR20230598A/es unknown
- 2022-06-27 CA CA3223223A patent/CA3223223A1/en active Pending
- 2022-06-27 AU AU2022301047A patent/AU2022301047A1/en active Pending
-
2023
- 2023-02-08 US US18/166,178 patent/US11970498B2/en active Active
- 2023-12-18 DO DO2023000280A patent/DOP2023000280A/es unknown
- 2023-12-28 CL CL2023003965A patent/CL2023003965A1/es unknown
-
2024
- 2024-01-12 CO CONC2024/0000237A patent/CO2024000237A2/es unknown
- 2024-01-25 EC ECSENADI20246831A patent/ECSP24006831A/es unknown
- 2024-03-14 US US18/605,248 patent/US12545684B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024524373A5 (enExample) | ||
| JP2023520333A5 (enExample) | ||
| US20220110941A1 (en) | Combinations for the treatment of neoplasms using quiescent cell targeting and inhibitors of mitosis | |
| JP6920709B2 (ja) | ベンゾチオフェン系選択的エストロゲン受容体ダウンレギュレーター | |
| KR101668931B1 (ko) | 항종양제의 효과 증강제 | |
| JP2024540483A5 (enExample) | ||
| JP2016526540A5 (enExample) | ||
| JP7123806B2 (ja) | 静止細胞標的化およびｅｇｆｒ阻害剤を用いた新生物の処置のための組み合わせ | |
| JP2014525464A (ja) | 置換ピラゾロ［３，４−ｄ］ピリミジンおよびその用途 | |
| JP2011513364A (ja) | Ｅｇｆｒ依存性疾患またはｅｇｆｒファミリーメンバーを標的とする薬剤に対して耐性を獲得した疾患を治療するためのピリミジン誘導体の使用 | |
| JP2023501950A (ja) | サイクリン依存性キナーゼ７（ｃｄｋ７）の阻害剤を用いてバイオマーカーにより特定された患者におけるがんを処置する方法 | |
| CN112010828A (zh) | Cdk7小分子抑制剂的化合物及其应用 | |
| EP3102571A1 (en) | Substituted pyrimidines useful as egfr-t790m kinase inhibitors | |
| Jin et al. | Targeting eIF4E signaling with ribavirin as a sensitizing strategy for ovarian cancer | |
| JP2019519573A (ja) | がんを処置するための方法 | |
| US20130143834A1 (en) | Cancer Treatment Method | |
| CN101222850A (zh) | 治疗对药物有抗性的癌症的方法 | |
| JP6445082B2 (ja) | ５’−ヒドロキシ−５−ニトロ−インジルビン−３’−オキシムを有効成分として含有する乳がん治療剤 | |
| JP5945863B2 (ja) | 腎細胞がん治療剤 | |
| WO2021025148A1 (ja) | 抗ｃｃｒ４抗体抵抗性のがんの治療剤 | |
| AU2016296997B2 (en) | Chlorobenzene substituted azaaryl compounds | |
| US9512076B2 (en) | Indirubin derivatives and uses thereof in treating chronic myelogenous leukemia | |
| JP2023500755A (ja) | 癌細胞成長抑制効果を示す新規なヘテロ環置換ピリミジン誘導体及びそれを含む薬剤学的組成物 | |
| TWI920088B (zh) | Ｓｉｋ-３抑制劑及其用途 | |
| US10512631B2 (en) | Chalcone compounds |